Trials / Completed
CompletedNCT03053219
Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 Treatment
An Open-Label, Non-Randomized, Single-Center Study to Preliminary Evaluation of Safety and Efficacy of Patients Who Participant in [14C] AC0010 Trail and Subsequent Receiving AC0010 Treatment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Hangzhou ACEA Pharmaceutical Research Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate safety and efficacy of male Patients With Advanced NSCLC who participant in \[14C\] AC0010 ADME.
Detailed description
The purpose of this study is to evaluate safety and efficacy of male Patients With Advanced NSCLC who participant in \[14C\] AC0010 ADME (absorption, distribution, metabolism and excretion) trial and subsequent receiving AC0010 treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AC0010 | Oral dose of 300mg bid,the two doses are advised to be administered at an interval of 12 hours |
Timeline
- Start date
- 2016-11-01
- Primary completion
- 2018-07-01
- Completion
- 2018-12-01
- First posted
- 2017-02-15
- Last updated
- 2019-02-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03053219. Inclusion in this directory is not an endorsement.